Increased volume of the calbindin D28k-labeled sexually dimorphic hypothalamus in genistein and nonylphenol-treated male rats.
Scallet
A C
AC
Division of Neurotoxicology National Center for Toxicological Research/FDA, Jefferson, Arkansas 72079, USA. ascallet@nctr.fda.gov
Divine
R L
RL
Newbold
R R
RR
Delclos
K B
KB
D000818:Animals; D015415:Biomarkers; D064092:Calbindin 1; D064026:Calbindins; D004396:Coloring Agents; D004032:Diet; D004305:Dose-Response Relationship, Drug; D004968:Estrogens, Non-Steroidal / Q000494:pharmacology*; D005260:Female; D019833:Genistein / Q000494:pharmacology*; D007031:Hypothalamus / Q000187:drug effects / Q000378:metabolism*; D007091:Image Processing, Computer-Assisted; D008297:Male; D010636:Phenols / Q000494:pharmacology*; D011301:Preoptic Area / Q000187:drug effects / Q000378:metabolism; D051381:Rats; D017207:Rats, Sprague-Dawley; D064030:S100 Calcium Binding Protein G / Q000378:metabolism*; D012727:Sex Characteristics
D015415:Biomarkers; C576500:Calb1 protein, rat; D064092:Calbindin 1; D064026:Calbindins; D004396:Coloring Agents; D004968:Estrogens, Non-Steroidal; D010636:Phenols; D064030:S100 Calcium Binding Protein G; C025256:nonylphenol; D019833:Genistein